]>
IRCT2017060828504N2 IRCT 2017-06-27 Vice chancellor for research of Iran University of Medical Sciences Effectiveness of combination of pharmachothrapy with metacognitive therapy versus pharmachotherapy in patient with posttraumatic stress disorder Effectiveness of combination of pharmachothrapy with metacognitive therapy versus pharmachotherapy in patient with posttraumatic stress disorder 2009-04-25 anticipated 6 Complete https://irct.ir/trial/23117 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Table of random numbers. N/A Post-traumatic stress disorder. Intervention 1: Intervention group1: (Drug treatment) Patients receive medication in addition, questionnaires: Clincian-Adminestered PTSD Scale (CAPS), beck anxiety (BAI), beck depression(BDI-II), Metacognition questonare (MCQ-30), subjective units of discomfort(SUDs), complete and general functioning will be assesed. Intervention 2: Intervention group2: Combination of pharmachothrapy with metacognitive therapy: Subjects complete CAPS, BDI-II, BAI, SUDs, MCQ-30, GAFs at pre test, post test and follow up.
public Mohsen Dadashi
Department of clinical psychology, Saadi street, zanjan,Iran
Zanjan Iran (Islamic Republic of) 4513615788 +98 242433534500 vida.yousefi@zums.ac.ir; mohsendadashi@zums.ac.ir Zanjan University of Medical Sciences scientific Mohsen Dadashi
Department of clinical psychology ,Zanjan University of Medical Sciences,
Zanjan Iran (Islamic Republic of) +98 24 3353 4500 vida.yousefi@zums.ac.ir; mohsendadashi@zums.ac.ir Zanjan University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: Having a chronic PTSD based on DSM-4 criterias؛ Do not receive psychological treatment before the study؛ In the case of using medicine, the possibility of keeping the type and dose of drugs during the study؛ Minimum 18 years and maximum 50 years، with at least third level education؛ The patient agreed to participate in the study and signed a written consent. Exclusion criteria: having a psychotic disorder and substance use disorder؛ Having full criteria for personality disorder in Axis II؛ There are risks for the patient such as having serious thoughts of suicide. 18 years 50 years Male F43.1 Post-traumatic stress disorder Treatment - Drugs Treatment - Other Intervention group1: (Drug treatment) Patients receive medication in addition, questionnaires: Clincian-Adminestered PTSD Scale (CAPS), beck anxiety (BAI), beck depression(BDI-II), Metacognition questonare (MCQ-30), subjective units of discomfort(SUDs), complete and general functioning will be assesed. Intervention group2: Combination of pharmachothrapy with metacognitive therapy: Subjects complete CAPS, BDI-II, BAI, SUDs, MCQ-30, GAFs at pre test, post test and follow up. Subjective unit of distress. Timepoint: Pre test, Post test, Follow up ( 1month), Follow up ( 2 month). Method of measurement: Subjective unit of distress scale. Anxiety. Timepoint: Pre test, Post test, Follow up ( 1 month) , Follow up ( 2 month). Method of measurement: Beck anxiety inventory. PTSD Signs. Timepoint: Pre test, Post test, Follow up ( 1 month) , Follow up ( 2 month). Method of measurement: PTSD Inventory. Depression. Timepoint: Pre test, Post test, Follow up(1 month), Follow up( month). Method of measurement: Beck depression inventory. Metacognition. Timepoint: Pre test, Post test, Follow up(1 month), Follow up(2 month). Method of measurement: Metacognition Questionnaire-30 (MCQ-30). General functioning. Timepoint: Pre test, Post test, Follow up ( 1 month),Follow up (2 month). Method of measurement: General assessment of functioning. -. Timepoint: -. Method of measurement: -. Vice chancellor for research of Iran University of Medical Sciences Approved 2010-09-23 Ethics committee of Iran University of Medical Sciences Shahid mansouri street, niyayesh street, satarkhan street,Tehran Tehran Iran (Islamic Republic of)